Correction to: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
The original article [1] contained two minor errors.
Main Authors: | Michael Berk, Alyna Turner, Gin S. Malhi, Chee H. Ng, Susan M. Cotton, Seetal Dodd, Yuval Samuni, Michelle Tanious, Claire McAulay, Nathan Dowling, Jerome Sarris, Lauren Owen, Astrid Waterdrinker, Deidre Smith, Olivia M. Dean |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-02-01
|
Series: | BMC Medicine |
Online Access: | http://link.springer.com/article/10.1186/s12916-019-1280-2 |
Similar Items
-
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
by: Michael Berk, et al.
Published: (2019-01-01) -
Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression
by: Olivia M. Dean, et al.
Published: (2015-03-01) -
Editorial: Placebo and Nocebo Effects in Psychiatry and Beyond
by: Katja Weimer, et al.
Published: (2020-08-01) -
N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial
by: Lauren Arancini, et al.
Published: (2019-09-01) -
Methotrexate Promotes Platelet Apoptosis via JNK-Mediated Mitochondrial Damage: Alleviation by N-Acetylcysteine and N-Acetylcysteine Amide.
by: Manoj Paul, et al.
Published: (2015-01-01)